Skye Bioscience, Inc. Increase (Decrease) in Derivative Liabilities
Skye Bioscience, Inc. (SKYE) reported Increase (Decrease) in Derivative Liabilities of $0 for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDerivativeLiabilities · last filed 2024-11-07
- Skye Bioscience, Inc. increase (decrease) in derivative liabilities for the quarter ending 2020-12-31 was $0.00.
- Skye Bioscience, Inc. increase (decrease) in derivative liabilities for fiscal 2021 was $0.00.
- Skye Bioscience, Inc. increase (decrease) in derivative liabilities for fiscal 2020 was $0.00.
| Period end | Increase (Decrease) in Derivative Liabilities 3 month | Increase (Decrease) in Derivative Liabilities 9 month | Increase (Decrease) in Derivative Liabilities 12 month |
|---|---|---|---|
| 2024-09-30 | $0.00 10-Q · filed 2024-11-07 | ||
| 2023-09-30 | -$3.00 10-Q · filed 2024-11-07 | ||
| 2021-12-31 | $0.00 10-K · filed 2022-03-28 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-02 | $0.00 10-K · filed 2021-03-02 | |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |